Julie R. Brahmer
0000-0002-2443-8395
Publication & Citation Trends
Most Cited Works
Publications
827 total
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Cited by 0
Semantic Scholar
Abstract 7424: Longitudinal and spatial heterogeneity of intra-tumoral TCR repertoires during immunotherapy in metastatic cancers
Cited by 0
Semantic Scholar
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events
Cited by 24
Semantic Scholar
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
Cited by 80
Semantic Scholar
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater PDF
Cited by 1,681
OpenAlex
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline PDF
Cited by 3,625
OpenAlex
Research Topics
Cancer Immunotherapy and Biomarkers
(410)
Lung Cancer Treatments and Mutations
(343)
Cancer Genomics and Diagnostics
(179)
Colorectal Cancer Treatments and Studies
(132)
Lung Cancer Research Studies
(122)
Frequent Co-Authors
Affiliations
University of Southern California
Uppsala University
University of Maryland, Baltimore
Indiana University Health
Translational Genomics Research Institute